Opentrons Labworks Secures $40M in Series E Funding

Opentrons Labworks Inc., a NYC-based company that specializes in open, AI-native laboratory automation, has raised $40 million in a Series E funding round.

The round was led by Avego with participation from BroadOak Capital Partners.

The company will use the funding to expand its robotics, software, and data infrastructure, advance AI-driven experimental execution, and enter new markets and geographies.

What is Opentrons Labworks?

Opentrons builds laboratory automation systems that help researchers run biological experiments with robots and software.

Read More:Rocker Secures $12.85M in Funding Led by Greycroft

Its Opentrons Flex® platform combines laboratory robots with AI systems, enabling researchers to design, run, and improve experiments through a continuous process. The company's open, API-driven technology connects AI models with physical laboratory equipment, helping researchers automate experimental workflows.

The platform serves academic research groups, diagnostics laboratories, and pharmaceutical companies. It aims to reduce the gap between AI-driven experiment design and the time required to carry out those experiments in physical laboratories.

How Much Funding Has Opentrons Labworks Raised?

Opentrons Labworks has raised $40 million in its Series E funding round. The company has not disclosed its total funding raised across previous rounds.

The latest investment will support the expansion of its robotics and software capabilities and the development of tools for autonomous science.

Who Invested in Opentrons Labworks’ Series E Round?

The $40 million Series E round was led by Avego.

BroadOak Capital Partners also participated in the funding round.

Why the Funding Matters

As AI tools make it faster to develop scientific hypotheses and design experiments, physical laboratories can become a bottleneck because experiments still need to be carried out and tested.

The funding will help the company improve its software and AI capabilities, expand the functions of its robots, and instruments, and integrate its technology more deeply into the wider laboratory automation ecosystem.

"Millions of scientists spend much of their day on manual work a robot can do. Giving that time back to discovery is the biggest opportunity in science," said James Atwood, PhD, CEO of Opentrons. "We made lab automation accessible for any lab, and our systems are built for AI to run experiments directly.

"Every AI-driven discovery still has to be tested in a real lab," said James Flexner, Managing Partner at Avego. "Drug developers and AI companies alike are moving experimental work forward toward automated workflows that generate usable data.

Market and Business Growth

Opentrons has deployed more than 11,000 robots across laboratories in over 80 countries. Its customers include academic institutions, diagnostics laboratories and pharmaceutical companies.

The company reports that its robots are used by 90% of the top 20 global pharmaceutical companies. It also has deployments at every top-20 US research university and 14 of the top 15 global biopharma companies.

What Happens Next?

Opentrons plans to scale its robotics, software, and data infrastructure while advancing its work in autonomous science.

The company will focus on faster protocol development through software and AI, expanding robot and instrument capabilities, and improving integration with other laboratory automation systems. It also plans to enter new markets and geographies.

Read More:Casap Raises $56M in Series B Funding Led by Base10 Partners